Validation batches of the vaccine against equine strangles Strangvac® is completed

3P Biopharmaceuticals, a leading CDMO specialized in the process development and GMP manufacturing of biologics has, together with the Swedish biotechnology company Intervacc AB and LIOF-Pharma (previously Praxis Pharmaceutical), completed the manufacturing process for the vaccine against equine strangles called Strangvac®

The validation production batches required for the forthcoming registration application to the European Medicines Agency, EMA, are thus finalized.

Submission of a registration application requires manufacturing of two batches in a scale that will be used for commercial production. The drug substance (antigens) for these batches have been produced during the summer and have been included as active components in the vaccine doses that now have been finalized. In total, 60.000 vials with vaccine doses have been manufactured and released.

Vaccine against equine strangles validation batches completed - 3P Bio

We are proud to go ahead successfully with Strangvac and the validation batches for the EMA’s application means that we are one step closer to achieve the approval for that vaccine,” said Dámaso Molero, General Manager at 3P Biopharmaceuticals. “The documentation on these two commercial batches is part of the dossier that we will submit to the European Medicines Agency (EMA).Now that we have manufactured the vaccine on a commercial scale that meets our specifications, we have passed another very important milestone towards an approved vaccine against strangles” says Andreas Andersson, CEO of Intervacc. Also, Tim Wood, VP CMC and Regulatory at Intervacc, who has worked intensively with the project, says: “We are very pleased with a robust, reliable and efficient manufacturing process.

The vaccine has been developed with a technology based on recombinant proteins that reduces the risk of serious side effects, which is a key characteristic in the new generation of vaccines based on that technique.

Original source:

Our dedicated team of specialists will be happy to discuss any of your CDMO needs. Contact us on +34 948 346 480 or email withinus@3pbio.com

Related Content

3P Biopharmaceuticals celebrates its 15th anniversary with Juan Carlos Unzué.

3P Biopharmaceuticals, a Navarre company founded in 2007, met with 370 employees in an exciting and joyful event looking back over its 15 years of trajectory.
Read more

3P Biopharmaceuticals and Biosergen complete together the manufacture of biomass for the Mucormycosis “Black Fungus” clinical phase II trial.

3P Biopharmaceuticals has completed the manufacture of BSG005 biomass planned for its client Biosergen. The client also recently announced Phase II clinical trial of BSG005 against Mucormycosis, otherwise known as the Black Fungus.
Read more

Regional Minister Irujo presents the Navarra Health Cluster

This morning, the Regional Minister for Economic and Business Development, Mikel Irujo, presented the Navarra Health Cluster, seeking to position the region as a European benchmark in personalized medicine, one of the priorities of the S4 Smart Specialisation Strategy. The initiative, which stems from the sector's demand and is led by a driving group, is now open to other companies and entities interested in participating.
Read more

Get in touch

Let’s discuss your biologics journey.

Discover more about our people, our passion, and how we can work together to improve lives.